Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
The CYBN news page on Stock Titan provides an archive of news releases and updates related to Cybin Inc., a Phase 3 clinical-stage neuropsychiatry and pharmaceutical company focused on developing next-generation treatment options for mental health conditions. These news items come directly from the company’s public communications and are also referenced in its Form 6-K filings with the U.S. Securities and Exchange Commission.
Readers can find coverage of Cybin’s clinical development programs, including updates on its lead candidates CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder, and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. News releases describe milestones such as trial enrollment progress, regulatory approvals to initiate studies in various countries, and participation in healthcare and investor conferences.
The news feed also includes information on Cybin’s capital markets activity, such as registered direct offerings of common shares and pre-funded warrants, the establishment and use of an at-the-market equity program, and the company’s stated intentions for the use of proceeds, including repayment of convertible debentures and funding of its clinical programs. Corporate updates, including plans to transfer its U.S. stock exchange listing from the NYSE American to the Nasdaq Global Market and the associated change in ticker symbol from CYBN to HELP, are documented in detail.
Because Cybin files many of these news releases as exhibits to Form 6-K, the CYBN news page serves as a convenient way to follow the narrative of its clinical progress, financing decisions, and listing changes over time. Investors and researchers can use this archive to review how the company describes its strategy in neuropsychiatry, its geographic operations in Canada, the United States, the United Kingdom, and Ireland, and its stated commitment to rigorous scientific research and regulatory compliance for its investigational compounds.
Cybin, a biopharmaceutical company, will have CEO Doug Drysdale presenting at the KCSA Psychedelics Virtual Investor Conference on April 28, 2022, at 11:00 a.m. ET. This live online event allows investors to interact and ask questions directly. Cybin focuses on developing therapeutics using psychedelics to address mental health issues through innovative drug discovery platforms and treatment regimens. Investors can register for the event via the provided link and access the archived webcast later.
Cybin Inc. has partnered with Clinilabs Drug Development Corporation to conduct a Phase 1/2a clinical trial for CYB003, a proprietary deuterated psilocybin analog, aimed at treating major depressive disorder (MDD). This marks the first evaluation of a psilocybin analog in clinical trials for MDD. The partnership is expected to expedite the regulatory pathway for CYB003, which has shown advantages in preclinical studies, including better tolerability and faster action compared to classic psilocybin. An IND filing with the FDA is anticipated in Q2 2022.
Cybin Inc. announced promising preclinical results for its proprietary drug CYB004, delivered via inhalation. The study indicates that inhaled CYB004 has a rapid onset, longer action duration, and over 40% improved bioavailability compared to inhaled DMT. These findings may position inhalation as a viable method for delivering therapeutic psychedelics. Cybin aims to address the limitations associated with IV administration of DMT in treating anxiety disorders. The company plans to file for a pilot study by Q2 2022 and commence it in Q3 2022.
Cybin Inc. (AMEX:CYBN) has announced the publication of an international patent application by the World Intellectual Property Organization (WIPO) covering inhalation delivery methods for various psychedelic molecules. This PCT application strengthens Cybin’s intellectual property position, particularly for its CYB004 pipeline program utilizing deuterated DMT via inhalation. The patent allows the company to pursue applications for multiple inhaled forms of psychedelics, aligning with its strategy of creating improved treatment options for mental health disorders.
Cybin announces participation in the Benzinga Psychedelics Capital Conference on April 19, 2022. CEO Doug Drysdale will engage in a fireside chat at 1:10 p.m. ET and a panel discussion at 3:10 p.m. ET focused on catalysts in the psychedelics industry. The event will be streamed live, and recordings will be available on the company’s investor relations website. Founded in 2019, Cybin is a biopharmaceutical firm dedicated to creating effective therapeutics for mental health issues, operating in multiple countries including Canada and the U.S.
Cybin Inc. has announced that its subsidiary, Adelia Therapeutics, has met a milestone outlined in a previous transaction agreement. This achievement will lead to the issuance of 22,428.3 Class B common shares, representing approximately $228,769 to Adelia shareholders. The shares can be exchanged for Cybin's common shares at a specific ratio. CEO Doug Drysdale expressed satisfaction with the progress, indicating it supports clinical development for psychedelic-based therapies. The company aims to advance innovative drug delivery systems for mental health disorders.
Cybin Inc. (AMEX:CYBN) has initiated a feasibility study utilizing Kernel's Flow technology to objectively measure the effects of ketamine on brain activity during psychedelic experiences. This study is poised to gather quantitative data, a significant advancement compared to previous subjective reporting methods. Authorized by the FDA in October 2021, the study will involve participants receiving either low-dose ketamine or a placebo. Cybin retains exclusive rights to innovations resulting from the study, reinforcing its commitment to advancing psychedelic therapies.
Cybin Inc. has completed in vivo preclinical studies of its deuterated psilocybin analog CYB003 for treating major depressive disorder (MDD). The studies indicate CYB003 is well-tolerated and shows promising pharmacological properties, including a 50% reduction in dosage variability and faster onset compared to classic psilocybin. The Company plans to submit an IND to the FDA in Q2 2022 and initiate Phase 1/2a trials by mid-2022, aiming to advance CYB003 as a potential treatment for MDD and alcohol use disorder.
Cybin Inc. announced milestones achieved by its subsidiary, Adelia Therapeutics, in accordance with a Transaction Agreement dated December 4, 2020. As a result, 90,546 Class B common shares will be issued to Adelia shareholders, fulfilling an obligation of approximately
Cybin Inc. (AMEX:CYBN) has announced the recruitment for a feasibility study evaluating the effects of ketamine on participants using Kernel Flow's neuroimaging technology. Participants will experience either a low dose of ketamine or a placebo, while their brain activity is monitored. This groundbreaking research aims to quantify psychedelic experiences, potentially paving the way for larger studies that bridge psychedelics and therapeutics. CEO Doug Drysdale emphasized the study's significance in enhancing understanding of psychedelic effects on mental health.
FAQ
What is the current stock price of Cybin (CYBN)?
What is the market cap of Cybin (CYBN)?
